<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970591</url>
  </required_header>
  <id_info>
    <org_study_id>Car-IBS 1511-01</org_study_id>
    <nct_id>NCT02970591</nct_id>
  </id_info>
  <brief_title>A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome</brief_title>
  <acronym>Car-IBS</acronym>
  <official_title>A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome; Traditional Dietary Advice Including Low FODMAP Content, vs a Low Carbohydrate Diet vs Optimized Medical Treatment for Adult Patients With IBS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <brief_summary>
    <textblock>
      Irritable Bowel Syndrome is a common disease to which there is no curable treatment. Diet is
      considered to trigger symptoms associated with the clinical picture of IBS, and dietary
      treatment is thus believed to relieve the symptoms of IBS. As the disease is very
      heterogeneous in its manifestation, different treatment options might be indicated depending
      on the predominant symptom. To investigate the response to different dietary treatment
      options, a randomized controlled intervention trial will be carried out in adult patients
      (&gt;18 y) with IBS according to Rome III criteria. The aim of this study is to compare the
      response to two different dietary treatments or optimized medical treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized controlled trial comparing three different treatments during four
      weeks:

        1. Combination of low FODMAP diet + traditional dietary advice (based on NICE
           recommendations)

             -  Eat at regular hours; 3 main meals and 3 snacks

             -  Eat in peace, chew the food properly

             -  Peel all fruits and vegetables

             -  Limit intake of spicy and fatty foods, coffe, alcohol, avoid fizzy drinks and
                chewing gum

             -  Choose soluble rather than insoluble fibres

             -  Avoid foods high in FODMAPs

        2. Diet low in carbohydrates

             -  10 E% carbohydrates, 25 E% protein, 65 E% fat

             -  Larger amounts of fish, shellfish, meat, egg, dairy products (lactose free if
                wanted) nuts, seeds, oil, vegetables

             -  No sugary or starchy foods, e.g pasta, potatoes, bread, rice, most fruits

             -  No specific consideration about FODMAP content

        3. Optimized pharmacological tretament based on predominant symptom and previous experience
           with pharmacological treatmment.

      Pain/discomfort:

        -  Pain: Amitriptyline 25 mg. Increase to 50 mg if needed

        -  Episodic pain: Hyoscyamine 0,2mg 2x2; adjust dose if needed

        -  Pain with diarrhea: Amitriptyline 25 mg. Increase dose if needed

        -  Pain with constipation: Linaclotide 290 microgram 1x1

      Constipation:

        -  Bulking agent (Sterculia gum (Inolaxol) 1x1. Increase to 1x3 if needed

        -  Osmotic laxative (Macrogol (Movicol) 1x1

        -  Linaclotide 290 microgram 1x1 Diarrhea

        -  Loperamide 1x2 . Adjust dose if needed

        -  Cholestyramine 1x1. Increase ever 3-5 d as needed

        -  Ondansetron 4mg 1x1. Increase to 1x2-3 if needed

        -  Eluxadoline 100mg 1x2

      Primary endpoint: IBS-SSS reduction &gt;50 points
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IBS-SSS</measure>
    <time_frame>Baseline, 4 weeks, 3 and 6 months</time_frame>
    <description>Primary endpoint: IBS-SSS reduction &gt;50 points @ 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic profile</measure>
    <time_frame>Baseline, 4 weeks, 6 months</time_frame>
    <description>Metabolomics in urine samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota content</measure>
    <time_frame>Baseline, 4 weeks, 6 months</time_frame>
    <description>Fecal microbiota analysis using 16S technique</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Diet B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low carbohydrate diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimized Medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Traditional dietary advice and low FODMAP content</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Traditional dietary advice and low FODMAP content</intervention_name>
    <description>Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.</description>
    <arm_group_label>Diet A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low carbohydrate diet</intervention_name>
    <description>Diet that contains a maximum of 10 energy percent of carbohydrates, 25 energy % proteins and 65 energy % fat.</description>
    <arm_group_label>Diet B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimized Medical treatment</intervention_name>
    <description>Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.</description>
    <arm_group_label>Medical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IBS according to ROME III criteria, BMI 18-35, ability to communicate on Swedish

        Exclusion Criteria:

          -  Heart, liver, neurologic or psychiatric disease or illness

          -  Serious gastrointestinal diseases

          -  Celiac disease

          -  Diabetes

          -  Other conditions or surgery that affects the gastrointestinal function

          -  Hyperlipidemia

          -  Food allergy or intolerance other than lactose

          -  Adherence to a specific diet

          -  Being pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Magnus Simren</name>
      <address>
        <city>Gothenburg</city>
        <state>Non-US/Non-Canadian</state>
        <zip>44331</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Simrén, MD, PhD</last_name>
      <phone>+46313421000</phone>
      <email>magnus.simren@medicine.gu.se</email>
    </contact>
    <investigator>
      <last_name>Magnus Simrén, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Magnus Simrén</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>FODMAPS</keyword>
  <keyword>carbohydrates</keyword>
  <keyword>metabolomics</keyword>
  <keyword>microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

